Cathie Wood’s ARK buys Guardant Health stock, sells Iridium

Hinge Health's Executive Chairman, Gabriel Mecklenburg, sold shares worth approximately $13.98 million on September 14, 2026. The sale involved converting 150,000 Class B shares into an equivalent amount of Class A shares, which were then sold at prices between $88.9793 and $94.7033 per share. Mecklenburg holds a total of 3,920,306 shares of Class B Common Stock, convertible into Class A shares, with direct holdings of 1,844,004 shares, and indirect holdings of 383,592 and 692,710 shares through trust arrangements.

The transaction was executed in accordance with a pre-approved Rule 10b5-1 trading plan. Hinge Health's stock price is near its 52-week high of $95.57, following a 113% increase over six months, but is currently deemed overvalued according to InvestingPro analysis. The company reported strong second-quarter earnings for 2026, surpassing expectations with earnings of $0.59 per share and revenue of $212.8 million, marking a 53% increase.

Hinge Health has also raised its full-year revenue and profit guidance, expanding into new areas like migraine and gastrointestinal care, and is set to acquire Cylinder Health for $105 million. Analysts have responded positively to these developments, with price targets ranging from $107 to $115.